Results 191 to 200 of about 24,414 (214)

Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use

Journal of Cardiovascular Pharmacology, 2023
Abstract: Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical trials, there is a dearth of use data on these agents in real-world settings.
Olivia M. Kim, Tatyana K. Givens, Emily G. Tang, Jennifer J. Schimmer, Tanya Ramsey, Kayla Boyd, Thomas Delate   +6 more
openaire   +2 more sources

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition

Biofactors, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has a crucial role in lipid metabolism, particularly due to its function in low‐density lipoprotein receptor degradation.
A. Cesaro, V. Bianconi, F. Gragnano, E. Moscarella, F. Fimiani, E. Monda, O. Scudiero, G. Limongelli, M. Pirro, P. Calabrò   +9 more
semanticscholar   +1 more source

Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: a systematic review and meta-analysis.

Journal of Cardiovascular Pharmacology, 2020
Lipoprotein(a) (Lp(a)) is a cardiovascular factor, for which there is no approved specific lowering treatment. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to have lowering effects on Lp(a).
I. Farmakis, I. Doundoulakis, A. Pagiantza, S. Zafeiropoulos, C. Antza, H. Karvounis, G. Giannakoulas   +6 more
semanticscholar   +1 more source

Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

Current Atherosclerosis Reports, 2013
The link between proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesterol metabolism was established only in 2003 when genetic mapping and positional cloning in patients with autosomal dominant hypercholesterolemia in which linkage to the loci coding for the LDL receptor and apolipoprotein B had been excluded identified the genetic defect ...
Evan A, Stein, Gary D, Swergold
openaire   +2 more sources

Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

Current Pharmaceutical Design, 2018
Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events.
Ali, Ali, Pierluigi, Costanzo, Angela, Hoye   +2 more
openaire   +2 more sources

Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus

Lupus, 2020
Background Low-density lipoprotein (LDL) levels are increased by proprotein convertase subtilisin kexin 9 (PCSK9) which targets the LDL receptor. We recently reported that PCSK9 ameliorates dendritic cell (DC) activation by oxidized LDL (OxLDL), which is
A. Liu, Mizanur Rahman, I. Hafström, S. Ajeganova, J. Frostegård   +4 more
semanticscholar   +1 more source

Proprotein convertase subtilisin/kexin type 9 related familial hypercholesterolaemia

The British Journal of Diabetes & Vascular Disease, 2012
Gain-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations are an uncommon cause of familial hypercholesterolaemia (FH) with a reported frequency of less than 2% in patients with FH in the United Kingdom. We have found a high prevalence of this genotype in our patients with FH in northwest England.
Sally L Hanton, Charles Van Heyningen
openaire   +1 more source

A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9

DNA and Cell Biology, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the most recently identified member of the proprotein convertase family. Genetic and cell biology studies have suggested a critical role of PCSK9 in regulating low-density lipoprotein receptor (LDLR) protein levels and thus modulating plasma LDL cholesterol. Recent data on the molecular basis for
Robert J, Schmidt, Youyan, Zhang, Yang, Zhao, Yue-Wei, Qian, He, Wang, Aimin, Lin, Maria E, Ehsani, Xiaohong, Yu, Guoming, Wang, Jaipal, Singh, Eric W, Su, Shuyu, Li, Robert J, Konrad, Guoqing, Cao   +13 more
openaire   +2 more sources

The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition.

American Journal of Cardiology, 2022
Michael A. Vavuranakis, S. Jones, E. Ziogos, M. Blaha, Marlene S Williams, Palmer L Foran, T. Schindler, S. Lai, S. Schulman, G. Gerstenblith, T. Leucker   +10 more
semanticscholar   +1 more source

Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Statin‐Associated Immune‐Mediated Necrotizing Myopathy: A Case Series

Arthritis & Rheumatology, 2019
To determine the safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with statin‐associated anti–3‐hydroxy‐3‐methlyglutaryl coenzyme A reductase (anti‐HMGCR)–positive immune‐mediated necrotizing myopathy (IMNM).
E. Tiniakou, Erika Rivera, A. Mammen, L. Christopher‐Stine   +3 more
semanticscholar   +1 more source